Maxim Group Reaffirms Their Hold Rating on Gilead Sciences

By Austin Angelo

Maxim Group analyst Gabrielle Zhou reiterated a Hold rating on Gilead Sciences (NASDAQ: GILD) today. The company’s shares opened today at $64.47, close to its 52-week low of $63.88.

Zhou noted:

“Gilead announced that four Phase III studies evaluating the triple combination of fixed-dose BIC/FTC/TAF (bictegravir 50 mg, emtricitabine/ tenofovir alafenamide 200/25 mg) for treatment of HIV-1 (treatment naïve and experienced) met their primary endpoints of non-inferiority (study details see below) vs. available regimens.”

According to TipRanks.com, Zhou is ranked 0 out of 5 stars with an average return of -16.2% and a 28.0% success rate. Zhou covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, ContraVir Pharmaceuticals Inc, and Sciclone Pharmaceuticals.

Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $80.10.

Gilead Sciences’ market cap is currently $84.3B and has a P/E ratio of 6.82. The company has a book value ratio of 4.1241.

Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is negative on the stock. Earlier this month, John C. Martin, the Chairman & CEO of GILD sold 73,333 shares for a total of $5,009,377.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Gilead Sciences, Inc. is a biopharmaceutical company, which discovers, develops and commercializes therapeutics for unmet medical need. It focuses on human immunodeficiency virus and liver diseases, such as chronic hepatitis C virus infection & chronic hepatitis B virus infection, hematology & oncology, and cardiovascular & inflammation as well as respiratory diseases. The company’s products include Descovy, Odefsey, Genvoya, Stribild, Complera, Atripla, Truvada, Viread, Emtriva, Tybost, Vitekta, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, Hepsera, Zydelig, Letairis, Ranexa, Lexiscan, Cayston, Tamiflu, AmBisome and Macugen. Gilead Sciences was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.